| 引用本文: | 钱哲,曹凯,钱佩佩,张潇菡,孙腾博.基于CHPS的亚胺培南西司他丁钠相关血小板减少症的危险因素分析[J].中国现代应用药学,2025,42(5):66-71. |
| Qian Zhe,Cao Kai,Qian Peipei,Zhang Xiaohan,Sun Tengbo.Risk Factors of Thrombopenia Related to Imipenem Cilastatin Sodium Based on CHPS[J].Chin J Mod Appl Pharm(中国现代应用药学),2025,42(5):66-71. |
|
| 摘要: |
| 目的 基于中国医院药物警戒系统（CHPS）探讨亚胺培南西司他丁钠相关血小板减少症的危险因素，为临床安全使用亚胺培南西司他丁钠提供参考。方法 利用CHPS建立评价方案，选取2017年4月1日至2022年4月1日在我院使用亚胺培南西司他丁钠治疗的住院患者。根据使用亚胺培南西司他丁钠后是否出现血小板减少症，将患者分为血小板减少症组和非血小板减少症组，比较两组患者的临床资料，分析亚胺培南西司他丁钠相关血小板减少症的危险因素。结果 共有559例患者纳入分析。其中，发生血小板减少症者136例，血小板减少症发生率为24.33%。多因素Logistic回归分析结果显示碱性磷酸酶、休克、血流感染、入住重症监护室、日剂量和用药时长是亚胺培南西司他丁钠相关血小板减少症的独立危险因素。结论 亚胺培南西司他丁钠可引起血小板减少症的发生，临床在使用亚胺培南西司他丁钠过程中，应关注伴有以上危险因素的患者，监测患者血小板计数水平，及时妥善进行临床诊治。 |
| 关键词: 亚胺培南西司他丁钠 血小板减少症 药品不良反应 危险因素 中国医院药物警戒系统 |
| DOI： |
| 分类号:R978.1 |
| 基金项目: |
|
| Risk Factors of Thrombopenia Related to Imipenem Cilastatin Sodium Based on CHPS |
|
Qian Zhe, Cao Kai, Qian Peipei, Zhang Xiaohan, Sun Tengbo
|
|
Xuchang Central Hospital Affiliated to Henan University of Science and Technology
|
| Abstract: |
| OBJECTIVE Risk factors of thrombopenia related to imipenem cilastatin sodium were explored based on China Hospital Pharmacovigilance System (CHPS), to provide reference for safely clinical use of imipenem cilastatin sodium. METHODS An evaluation plan was constructed in CHPS to select inpatients treated with imipenem cilastatin sodium in our hospital from Apr 1st, 2017 to Apr 1st, 2021. According to whether thrombopenia had happened, patients were divided into thrombopenia group and non?thrombopenia group. Clinical characteristics between the two groups were compared. The risk factors of thrombopenia related to imipenem cilastatin sodium were analyzed using the multivariable logistic regression model. RESULTS A total of 559 patients were enrolled into this study. Among them, 136 patients developed thrombopenia. The incidence of thrombopenia was 24.33%. Result of multivariate logistic regression analysis showed that alkaline phsphatase, shock, bloodstream infection, admission to intensive care units, daily dose and treatment course were independent risk factors of thrombopenia related to imipenem cilastatin sodium. CONCLUSION Imipenem cilastatin sodium can induce thrombopenia. Attentions should be paid to patients with risk factors mentioned above, and platelet count should be monitored when patients are treated with imipenem cilastatin sodium in order to take timely and proper diagnosis and treatment. |
| Key words: imipenem cilastatin sodium thrombopenia adverse drug reaction risk factor China Hospital Pharmacovigilance System |
